ADCT on NYSE
ADC Therapeutics SA
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Alimera Sciences, Arcturus Therapeutics or Fulcrum Therapeutics (United States), or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 90% of the revenue ADC Therapeutics SA broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2024 | 2025 |
|---|---|---|
| Product | $69.3M | $73.6M |
| License Revenues | $0 | $5.0M |
| Royalty Revenue | $1.6M | $2.8M |
Regions
United States brought in 90% of the revenue ADC Therapeutics SA broke down this way in fiscal 2025.
Regions by year
| Regions | 2024 | 2025 |
|---|---|---|
| United States | $69.3M | $73.6M |
| EMEA | $1.6M | $7.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue5¢$5.8M
- Research and development94¢$104.0M
- Income tax1¢$1.0M
Out of $81.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue, net | $81.4M | $70.8M |
| Cost of product sales | -$5.8M | -$5.9M |
| Research and development | -$104.0M | -$109.6M |
| Selling and marketing | -$43.4M | -$44.0M |
| General and administrative | -$36.6M | -$41.9M |
| Restructuring, impairment and other related costs | -$13.1M | $0 |
| Total operating expense | -$202.9M | -$201.5M |
| Loss from operations | -$121.5M | -$130.7M |
| Interest income | $8.8M | $12.3M |
| Interest expense | -$51.6M | -$50.2M |
| Other, net | $22.7M | $12.5M |
| Total other expense, net | -$20.1M | -$25.5M |
| Loss before income taxes | -$141.6M | -$156.1M |
| Income tax expense | -$1.0M | -$166.0K |
| Loss before equity in net losses of joint venture | -$142.6M | -$156.3M |
| Equity in net losses of joint venture | $0 | -$1.5M |
| Net loss | -$142.6M | -$157.8M |
| Net loss per share, basic (in dollars per share) | -$1.12 | -$1.62 |
| Net loss per share, diluted (in dollars per share) | -$1.12 | -$1.62 |
| Weighted average shares outstanding, basic (in shares) | 127.1M shares | 97.2M shares |
| Weighted average shares outstanding, diluted (in shares) | 127.1M shares | 97.2M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $261.3M | $250.9M | |
| Accounts receivable, net | $29.1M | $20.3M | |
| Inventory | $4.2M | $2.3M | |
| Prepaid expenses | $5.6M | $8.4M | |
| Other current assets | $6.1M | $9.4M | |
| Total current assets | $306.3M | $291.3M | |
| Inventory, long-term | $14.3M | $16.1M | |
| Property and equipment, net | $0 | $5.1M | |
| Operating lease right-of-use assets | $1.3M | $8.4M | |
| Other long-term assets | $1.2M | $1.2M | |
| Total assets | $323.1M | $322.0M | |
| Accounts payable | $9.2M | $18.0M | |
| Accrued expenses and other current liabilities | $58.0M | $62.4M | |
| Senior secured term loans, current portion | $3.0M | $0 | |
| Total current liabilities | $70.2M | $80.5M | |
| Deferred royalty obligation, long-term | $322.5M | $320.1M | |
| Senior secured term loans, long-term | $112.5M | $113.6M | |
| Operating lease liabilities, long-term | $1.0M | $8.0M | |
| Other long-term liabilities | $2.8M | $2.4M | |
| Total liabilities | $509.0M | $524.6M | |
| Common shares, at CHF 0.08 par value | $11.1M | $8.4M | |
| Additional paid-in capital | $1.4B | $1.3B | |
| Treasury shares | -$205.0K | -$220.0K | |
| Accumulated other comprehensive loss | -$517.0K | -$1.4M | |
| Accumulated deficit | -$1.6B | -$1.5B | |
| Total shareholders (deficit) equity | -$185.8M | -$202.6M | -$148.2M |
| Total liabilities and shareholders (deficit) equity | $323.1M | $322.0M | |
| Common shares, par value (in CHF per share) | 0.08 CHF | 0.08 CHF | |
| Common shares issued (in shares) | 128.3M shares | 101.6M shares | |
| Common shares outstanding (in shares) | 125.7M shares | 98.9M shares | |
| Treasury shares (in shares) | 2.6M shares | 2.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$142.6M | -$157.8M |
| Share-based compensation expense | $6.9M | $6.6M |
| Accretion expense of deferred royalty obligation | $29.1M | $28.2M |
| Cumulative catch-up adjustment, deferred royalty obligation | -$22.2M | -$11.2M |
| Write-downs of inventory | $2.3M | $1.5M |
| Depreciation | $705.0K | $1.3M |
| Amortization of operating lease right-of-use assets | $1.2M | $1.9M |
| Share of results in joint venture | $0 | $1.5M |
| Amortization of debt discount, senior secured term loan | $1.8M | $902.0K |
| Impairment of long-lived assets and prepaid expenses and other related costs | $6.7M | $0 |
| Other | $304.0K | -$669.0K |
| Accounts receivable, net | -$8.8M | $4.8M |
| Inventory | -$2.4M | -$3.7M |
| Prepaid expenses and other current assets | $5.2M | -$1.5M |
| Other long-term assets | -$46.0K | -$456.0K |
| Accounts payable | -$9.0M | $2.5M |
| Accrued expenses and other current liabilities | -$7.4M | $11.1M |
| Operating lease liabilities | -$2.5M | -$2.0M |
| Other long-term liabilities | -$410.0K | -$6.9M |
| Net cash used in operating activities | -$141.2M | -$123.8M |
| Payment for purchases of property and equipment | -$264.0K | -$867.0K |
| Proceeds from the sale of equipment | $659.0K | $0 |
| Net cash provided by (used in) investing activities | $395.0K | -$867.0K |
| Proceeds from sale of common shares, net of transaction costs | $86.3M | $60.5M |
| Proceeds from Pre-Funded Warrants, net of transaction costs | $65.4M | $36.9M |
| Proceeds from share issuance under stock purchase plan | $271.0K | $558.0K |
| Proceeds from the exercise of options | $534.0K | $228.0K |
| Taxes paid related to net settled equity awards | -$1.5M | -$1.2M |
| Net cash provided by financing activities | $150.9M | $97.1M |
| Net decrease in cash and cash equivalents | $10.2M | -$27.6M |
| Exchange (losses)/gains on cash and cash equivalents | $305.0K | -$83.0K |
| Interest paid | $14.5M | $15.7M |
| Interest received | $8.8M | $13.7M |
| Payments made under royalty financing transaction | -$6.2M | -$5.4M |
| Transaction costs recorded in Accounts payable and other current liabilities and Other long-term liabilities | $837.0K | $0 |
Recent filings
- Oct 13, 20268-K
- Aug 14, 2026SCHEDULE 13G
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Aug 13, 2026S-8
- Jul 27, 2026SCHEDULE 13G
- Jul 2, 20268-K
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jul 2, 20264
- Jun 24, 20268-K
- Jun 3, 20268-K
- Jun 3, 20264
- Jun 3, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10